首页|肺癌药物靶点与Nur77的研究进展

肺癌药物靶点与Nur77的研究进展

扫码查看
肺癌是对人类健康和生命造成重大威胁的恶性肿瘤之一,死亡率位居癌症之首.肺癌的治疗主要包括手术、放射、药物、免疫治疗等,存在治疗费用高、毒副作用大、疗效有限等问题,需要不断发现新的有效治疗手段.现有研究表明:核受体超家族成员孤儿核受体Nur77 在癌症的发生和发展中起着重要作用,Nur77 能够通过高表达和易位到线粒体,诱导肺癌细胞凋亡,有望成为治疗肺癌的潜在药物靶点.通过综述近年来肺癌相关的药物靶点与Nur77 及其相关化合物,展望了未来的研究方向,为肺癌治疗尤其是靶向药物治疗提供了新思路和理论依据.
Advancement on Anti-lung Cancer Target and Nur77
Lung cancer is one kind of malignant tumors that seriously threatens human health and life,with the first mortality among all cancers.The present treatment of lung cancer mainly includes surgery,radiation,drugs and immuno-therapy,with the problems such as high cost,strong toxicities or adverse reactions,and limited curative effect.It is neces-sary to constantly find new effective treatments.Previous studies have shown that Nur77,a member of nuclear receptor su-perfamily,plays an important role in the genesis and development of cancer.Furthermore,Nur77 can induce apoptosis of lung cancer cells through its high expression and translocation to mitochondria,which may be a potential target for lung cancer treatment.The current review focus on the drug targets related to lung cancer and Nur77 and its related com-pounds in recent reports,and the trends of future research,which will aid new strategy or theoretical basis for lung can-cer treatment,especially target drug therapy.

lung cancertarget drugsNur77target therapy

潘莉分、李祯烨、劳茹阳、胡琼莹

展开 >

台州学院 医学院,浙江 台州 318000

肺癌 靶向药物 Nur77 靶向治疗

浙江省基础公益研究计划项目浙江省公益性技术应用研究(实验动物)项目

LGF21H2800022016C37143

2023

台州学院学报
台州学院

台州学院学报

CHSSCD
影响因子:0.283
ISSN:1672-3708
年,卷(期):2023.45(6)
  • 11